IL-2 ( DrugBank: IL-2 )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
46	悪性関節リウマチ	34
49	全身性エリテマトーデス	5
53	シェーグレン症候群	3
56	ベーチェット病	3

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04952155 (ClinicalTrials.gov)	January 1, 2020	27/6/2021	Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome	A Single-center, Open-label Clinical Study to Evaluate the Efficacy and Safety of Low-dose IL-2in th ...	Amyotrophic Lateral Sclerosis	Drug: IL-2	Peking University Third Hospital	NULL	Recruiting	18 Years	70 Years	All	13	Phase 2	China
2	NCT03039673 (ClinicalTrials.gov)	June 19, 2017	31/1/2017	MIROCALS: Modifying Immune Response and OutComes in ALS	Efficacy and Safety of Low-dose IL-2(Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation ...	Amyotrophic Lateral Sclerosis	Drug: Riluzole;Drug: IL-2;Drug: 5% glucose water solution	Centre Hospitalier Universitaire de Nimes	NULL	Completed	18 Years	75 Years	All	304	Phase 2	France;United Kingdom
3	EUCTR2015-005347-14-GB (EUCTR)	25/08/2016	09/05/2016	Efficacy and safety of low-dose IL-2(ld-IL-2) as a Treg enhancer for controlling neuro-inflammation ...	Efficacy and safety of low-dose IL-2(ld-IL-2) as a Treg enhancer for controlling neuro-inflammation ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term ...	Trade Name: Proleukin 18 MUI Product Name: proleukin	CHU DE NIMES	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	216	Phase 2	United Kingdom
4	NCT02059759 (ClinicalTrials.gov)	September 2015	7/2/2014	Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low D ...	Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low D ...	Amyotrophic Lateral Sclerosis	Drug: Placebo;Drug: 1.0 MIU IL-2 per day;Drug: 2.0 MIU IL-2 per day	Centre Hospitalier Universitaire de Nimes	NULL	Completed	18 Years	75 Years	Both	36	Phase 2	France

First Previous1Next Last

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 10 of 34 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-INR-16009546	2016-11-01	2016-10-21	The Efficacy and Safety of Low Dose IL-2Conbined IL-6 Antagonist Therapy in Chinese Over-treated Pat ...	The Efficacy and Safety of Low Dose IL-2Conbined IL-6 Antagonist Therapy in Chinese Over-treated Pat ...	rheumatoid arthritis;M05.901	IL-2group:lL-2;IL-2+ IL-6 antagonist group:Tocilizumab;non IL-2or IL-6 antagonist group:glucocortico ...	the Second Hospital of Shanxi Medical University	NULL	Recruiting	18	65	Both	IL-2 group:15;IL-2 + IL-6 antagonist group:15;non IL-2 or IL-6 antagonist group:15;		China
2	NCT02467504 (ClinicalTrials.gov)	July 1, 2015	4/6/2015	Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-do ...	Rheumatoid Arthritis	Drug: hrIL-2 active;Drug: hrIL-2 placebo;Drug: MTX;Drug: Folic Acid;Drug: Loxoprofen	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Completed	18 Years	70 Years	All	47	Phase 2	China
3	NCT02097264 (ClinicalTrials.gov)	September 2014	24/3/2014	A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biop ...	A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating ...	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: Adalimumab;Drug: placebo	Novo Nordisk A/S	NULL	Withdrawn	18 Years	75 Years	Both	0	Phase 2	Ireland;Portugal;Spain;United Kingdom
4	EUCTR2013-001492-20-PT (EUCTR)	05/03/2014	24/01/2014	A trial investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biop ...	A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating ...	Rheumatoid arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Other descriptive name: NNC0109-0012 Trade ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	42	Phase 2	Portugal;Spain;Ireland;United Kingdom
5	EUCTR2013-001492-20-ES (EUCTR)	31/01/2014	16/01/2014	A trial investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biop ...	A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating ...	Rheumatoid arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Other descriptive name: NNC0109-0012 Trade ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	42	Phase 2	Portugal;Spain;Ireland;United Kingdom
6	EUCTR2013-001492-20-GB (EUCTR)	24/12/2013	18/10/2013	A trial investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biop ...	A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating ...	Rheumatoid arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Other descriptive name: NNC0109-0012 Trade ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	42	Phase 2	Portugal;Hungary;Czech Republic;Spain;Belgium;Poland;Ireland;Germany;Netherlands;Italy;United Kingdo ...
7	EUCTR2012-000609-58-CZ (EUCTR)	22/05/2013	21/06/2012	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who ar ...	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by a ...	Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Product Code: 0109-0012A 50 mg/ml INN or Pr ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	268	Phase 2	United States;Spain;Ukraine;Russian Federation;Italy;United Kingdom;Czech Republic;Hungary;Mexico;Eu ...
8	EUCTR2012-000610-11-CZ (EUCTR)	22/05/2013	20/06/2012	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who ar ...	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by a ...	Rheumatoid arthritis MedDRA version: 17.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Product Code: 0109-0012A 50 mg/ml INN or Pr ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	298	Phase 2	United States;Spain;Ukraine;Russian Federation;Italy;Czech Republic;Hungary;European Union;Mexico;Ca ...
9	EUCTR2012-000610-11-BE (EUCTR)	20/02/2013	14/06/2012	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who ar ...	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by a ...	Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Product Code: 0109-0012A 50 mg/ml INN or Pr ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	268	Phase 2	United States;Spain;Ukraine;Russian Federation;Italy;Hungary;Czech Republic;Mexico;European Union;Ca ...
10	EUCTR2012-000609-58-BE (EUCTR)	20/02/2013	14/06/2012	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who ar ...	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by a ...	Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: 0109-0012A 100 mg/ml INN or Proposed INN: N/A Product Code: 0109-0012A 50 mg/ml INN or Pr ...	Novo Nordisk A/S	NULL	Not Recruiting			Female: yes Male: yes	268	Phase 2	United States;Spain;Ukraine;Russian Federation;Italy;United Kingdom;Hungary;Czech Republic;Mexico;Eu ...

First Previous1 2 3 4Next Last

先頭へ

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05262686 (ClinicalTrials.gov)	April 1, 2022	22/2/2022	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2in the Treatment of Systemic Lu ...	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2in the Treatment of Systemic Lu ...	Systemic Lupus Erythematosus	Drug: Belimumab;Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	70 Years	All	10	Phase 3	China
2	NCT04077684 (ClinicalTrials.gov)	September 10, 2019	1/9/2019	Efficacy and Safety of Low-dose IL-2in Patients With SLE: a Multicenter, Randomised, Placebo-control ...	Efficacy and Safety of Low-dose Interleukin-2 in Patients With Systemic Lupus Erythematosus: a Multi ...	Systemic Lupus Erythematosus	Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	75 Years	All	500	Phase 2	China
3	ChiCTR-IPR-16009451	2016-11-01	2016-10-16	The Efficacy and Safety of Low Dose IL-2Conbined Rapamycin Therapy in Chinese Over-treated Patients ...	The Efficacy and Safety of Low Dose IL-2Conbined Rapamycin Therapy in Chinese Over-treated Patients ...	Systemic Lupus Erythematosus	IL-2group:IL-2;IL-2+ Rapamycin group :IL-2and Rapamycin;non IL-2or IL-6 antagonist group :Glucocorti ...	the Second Hospital of Shanxi Medical University	NULL	Pending	18	80	Both	IL-2 group:20;IL-2 + Rapamycin group :20;non IL-2 or IL-6 antagonist group :20;		China
4	NCT02932137 (ClinicalTrials.gov)	May 5, 2016	8/10/2016	Anti-infection of Low-does IL-2 in SLE	Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE	Systemic Lupus Erythematosus	Drug: Interleukin-2	Peking University People's Hospital	NULL	Completed	18 Years	60 Years	All	30	N/A	China
5	NCT02084238 (ClinicalTrials.gov)	August 2013	8/3/2014	Low-dose IL-2( Interleukin-2) Treatment in SLE	Safety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Interleukin-2	Peking University People's Hospital	Monash University	Completed	18 Years	65 Years	All	40	N/A	China

First Previous1Next Last

先頭へ

53. シェーグレン症候群

臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05605665 (ClinicalTrials.gov)	November 5, 2022	29/10/2022	Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome	Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome	Sjögren's Syndrome	Drug: low-dose interleukin-2;Drug: rapamycin	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	China
2	ChiCTR-INR-17011220	2017-04-24	2017-04-23	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome ...	primary Sj?gren’s syndrome	Ll-2 group:IL-2 treatment; non IL-2 group:conventional treatment;	the Second Hospital of Shanxi Medical University	NULL	Recruiting			Both	Ll-2 group:90; non IL-2 group:90;		China
3	NCT02464319 (ClinicalTrials.gov)	June 1, 2015	30/5/2015	A Phase II Study With Low-dose Recombinant Human IL-2for the Treatment of Primary Sjögren's Syndrome ...	Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Drug: hrIL-2 active;Drug: hrIL-2 placebo	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Completed	18 Years	65 Years	All	60	Phase 2	China

First Previous1Next Last

56. ベーチェット病

臨床試験数 : 81 / 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04065672 (ClinicalTrials.gov)	November 12, 2019	20/8/2019	Low-dose IL-2 Treatment on Behcet's Disease	Low-dose IL-2 Treatment on Behcet's Disease	Behcet's Disease	Drug: Low-dose IL-2	Peking University People's Hospital	NULL	Recruiting	18 Years	70 Years	All	15	Phase 2	China
2	NCT02648581 (ClinicalTrials.gov)	June 14, 2017	21/12/2015	Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With B ...	A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal An ...	Behçet Disease	Drug: Subcutaneous Ustekinumab	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	16	Phase 2	France
3	EUCTR2015-002190-37-FR (EUCTR)	30/10/2015	12/01/2016	A Study to Evaluate the Efficacy and Safety of Ustekinumab in patients with Behçet disease	A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal An ...	Behçet diseaseSTELABEC-1: patients with oral ulcersSTELABEC-2 : patients with active posterior uveit ...	Trade Name: STELARA Product Name: STELARA INN or Proposed INN: Ustekinumab	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France

First Previous1Next Last

先頭へ